

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ni, et al.

Confirmation No.: 7025

Application Serial No: 09/933,767

Group Art Unit: 1634

Filed: August 22, 2001

Examiner: Bradley L. Sisson

Title: 207 Human Secreted Proteins

Atty. Docket No.: PZ007P2

INFORMATION DISCLOSURE
STATEMENT PURSUANT TO 37 § CFR 1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56, 1.97 and 1.98 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-AG listed on the attached Form PTO/SB/08A. A copy of each of reference(s) AA-AG is enclosed.

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:106 and the corresponding cDNA clone of this application is related to SEQ ID NOS:68688 and 105553 in co-pending U.S. Patent Application Serial No. 09/912,293, filed July 26, 2001. A legible copy of that portion of U.S. Patent Application Serial No. 09/912,293, which caused it to be listed on the attached revised form PTO/SB/08 is submitted herewith as reference AA.


The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning the PTO duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application and consider the information contained therein during the prosecution of this application.

Identification of the listed reference(s) is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Respectfully submitted,

Dated: September 16, 2004



Kenley K. Hoover (Reg. No. 40,302)
Attorney for Applicants

Human Genome Sciences, Inc.
14200 Shady Grove Road
Rockville, MD 20850
Telephone: (301) 610-5771



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/933,767-Conf. #7025
				Filing Date	August 22, 2001
				First Named Inventor	Jian Ni
				Art Unit	1634
				Examiner Name	Bradley L. Sisson
Sheet	1	of	1	Attorney Docket Number	PZ007P2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-09/912,293	NOT PUBLISHED	ROSEN, et al.	pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOS: 68688 and 105553

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	AB	BRONSTEIN, et al., "Oligodendrocyte-specific protein (OSP) is a major component of CNS myelin," <i>J Neurosci Res.</i> , 50(5):713-720 (December 1, 1997)		
	AC	KATAHIRA, et al., "Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo," <i>J Biol Chem.</i> , 272(42):26652-26658 (October 17, 1997)		
	AD	KATAHIRA, et al., "Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin," <i>J Cell Biol.</i> , 136(6):1239-1247 (March 24, 1997)		
	AE	SIROTKIN, et al., "Identification, characterization, and precise mapping of a human gene encoding a novel membrane-spanning protein from the 22q11 region deleted in velo-cardio-facial syndrome," <i>Genomics</i> , 42(2):245-251 (June 1, 1997)		
	AF	MICHL, et al., "Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer," <i>Cancer Res.</i> , 63(19):6265-6271 (October 1, 2003)		
	AG	NICHOLS, et al., "Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target," <i>Am J Clin Pathol.</i> , 121(2):226-230 (February 2004)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--